Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 85,906 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Healthy
Interventions: Technosphere Insulin Inhalation Powder using the Gen2C inhaler, Regular Human Insulin; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Foot Ulcers, Osteomyelitis, Amputation
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: HIV-1-infection
Interventions: IAP086 0.3 mcg/kg, IAP086 1 mcg/kg, IAP086 3 mcg/kg, IAP086 6 mcg/kg, IAP086 10 mcg/kg, IAP086 15 mcg/kg, IAP086 25 mcg/kg, IAP086 32 mcg/kg, IAP086 40 mcg/kg; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Recurrent Merkel Cell Carcinoma, Stage III Merkel Cell Carcinoma AJCC v7, Stage IIIA Merkel Cell Carcinoma AJCC v7, Stage IIIB Merkel Cell Carcinoma AJCC v7, Stage IV Merkel Cell Carcinoma AJCC v7
Interventions: Laboratory Biomarker Analysis, Pembrolizumab; Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 13
States / cities: Palo Alto, California • San Francisco, California • New Haven, Connecticut + 9 more

Conditions: Gastroesophageal Reflux Disease, GERD, Gastroparesis
Interventions: Domperidone; Drug
Lead sponsor: Scott Gabbard, MD; Other
Eligibility: 18 Years and older
U.S. locations: 2
States / cities: Weston, Florida • Cleveland, Ohio

Conditions: Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions: Laboratory Biomarker Analysis, Selinexor; Other · Drug
Lead sponsor: University of Chicago; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sleep Apnea, Obstructive
Interventions: Reach for Equity in Pediatric Obstructive Sleep Evaluation (REPOSE), Usual Care; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 2 Years to 12 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Gram Positive Infection, Concurrent Antibiotic Treatment
Interventions: daptomycin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 2 Years to 6 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Pancreatic Cancer
Interventions: Onvansertib, NALIRIFOX; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Lymphoma
Interventions: bexarotene, methoxsalen, UV light therapy; Drug · Procedure
Lead sponsor: Millennix; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 19
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Stanford, California + 14 more

Conditions: Alzheimer Disease, Dementia
Interventions: Old SCHOOL Hip-Hop (Dementia Education), My Plate (Nutrition Education); Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: ALK-positive Advanced Tumors
Interventions: ceritinib, warfarin, midazolam; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Detroit, Michigan • San Antonio, Texas

Conditions: Colorectal Cancer
Interventions: Azacitidine, Capecitabine, Oxaliplatin, Azacitidine MTD; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mild Neurocognitive Disorder, Healthy Aging
Interventions: Transcranial Focused Ultrasound; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 50 Years to 85 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Advanced Solid Cancers, Hematologic Cancers
Interventions: SRF231; Drug
Lead sponsor: Surface Oncology; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: New York, New York • San Antonio, Texas

Conditions: Non-invasive Neuromodulation in Healthy Subjects
Interventions: Inhibitory rTMS (1 Hz), Excitatory rTMS (5 Hz); Device
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years to 40 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bipolar Disorder, Insulin Resistance
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pmm2-CDG, CDG1A
Interventions: Placebo, Acetazolamide; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 4 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Rochester, Minnesota • Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Colorectal Cancer Metastatic
Interventions: CT scan; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: HIV Infections
Interventions: GSK1265744 30mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota

Conditions: Gastroesophageal Cancer
Interventions: nab-paclitaxel, ramucirumab; Drug · Biological
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 11
States / cities: Denver, Colorado • Fort Myers, Florida • Orlando, Florida + 8 more

Conditions: Human Papillomavirus
Interventions: Gardasil; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 27 Years to 45 Years · Male only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Toxicity
Interventions: transdermal DMPS; Drug
Lead sponsor: Banner Health; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Bortezomib, Total-Body Irradiation, Melphalan, Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Laboratory Biomarker Analysis; Drug · Radiation · Procedure + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler

Investigation of the Use of Hyperspectral Imaging in Foot Surgery Patients

IAP-086-1: A Phase 1 Single Ascending Dose First-Time in Human Study

Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer

Treatment Use of Domperidone for Gastroparesis

Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

The REPOSE (Reach for Equity in Pediatric Sleep Evaluation) Navigation Intervention

PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections

Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma

Old School Hip Hop: Parent Follow-Up & Spanish Speakers Inclusion

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

Azacitidine and CAPOX in Metastatic Colorectal Cancer

tFUS for Memory in mNCD and Healthy Adults

Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers

Mechanisms of Non-Invasive Neuromodulation Interventions: Influence on Human Neurochemistry and Functional Connectivity

Pioglitazone for the Treatment of Bipolar Depression

Acetazolamide Efficacy in Ataxia in PMM2-CDG

Assessing How Normal Variations in CT Scanning Affects Its Interpretation

A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

Study of Gardasil in Mid-Adult Males (MAM)

Transdermal Absorption of Dimercaptopropane-1-Sulfonate (DMPS) and Effect on Urinary Mercury Excretion

Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma